Allogene Therapeutics reported a personal stock transaction by its president and chief executive, Chang David D., who sold 95,269 shares of common stock on February 2, 2026, according to a regulatory filing. The sale generated $171,484, with execution prices ranging from $1.71 to $1.87 per share.
The filing specifies that the disposition was performed to satisfy tax withholding obligations stemming from the vesting of restricted stock units and was required under the company’s equity incentive plan. After the sale, Chang retained direct ownership of 5,185,862 shares of Allogene Therapeutics.
Alongside the share sale, the filing records additional equity-related activity for Chang. He acquired 1,387,931 shares by exercising stock options priced at $1.87, with those options carrying an expiration date of February 2, 2036. The filing also shows the grant or acquisition of 392,586 restricted stock units.
The document further details indirect holdings attributable to Chang across several trusts: 856,044 shares in the RTC 2019 Trust, 856,044 shares in the JEC 2019 Trust, and 1,201,108 shares in the Chang 2006 Family Trust.
Allogene’s equity has been on an upward trajectory in recent periods, gaining 13.21% over the past week and rising 60.71% over the prior six months. A valuation analysis cited in relation to the company indicates that it appears undervalued relative to its Fair Value.
Corporate and clinical developments accompany the insider transaction. In its third-quarter 2025 results, Allogene posted an earnings per share of -$0.19, outperforming analyst expectations of -$0.22 and representing a positive surprise of 13.64%.
The filing and related disclosures also recount a favorable arbitration ruling that reaffirmed the company’s control over its cell therapy cemacabtagene ansegedleucel in principal markets including the United States and Europe. The ruling is described as clearing the path for Allogene to obtain full global commercialization rights to the therapy.
Analyst coverage has shifted in response to recent data and company developments. Citizens upgraded the stock to Market Outperform, citing promising clinical data with high response rates for the company’s cell therapy program. UBS initiated coverage with a Buy rating and assigned a price target of $8.00.
Looking ahead, Allogene announced notable clinical milestones for 2026, emphasizing potential progress for its allogeneic CAR T platform across oncology and autoimmune indications. Company statements position these initiatives as laying the groundwork for potentially transformative growth.
Context and implications
The insider sale, described as a tax-withholding-driven transaction tied to RSU vesting, is presented in the filing alongside broader corporate and clinical signals that investors and market participants are weighing: recent strong share performance, a better-than-expected quarterly EPS outcome, an arbitration decision affecting commercialization rights, analyst upgrades, and planned 2026 clinical milestones.